PT3057965T - Formas de sal e cristal de inibidor de plk-4 - Google Patents

Formas de sal e cristal de inibidor de plk-4

Info

Publication number
PT3057965T
PT3057965T PT14854037T PT14854037T PT3057965T PT 3057965 T PT3057965 T PT 3057965T PT 14854037 T PT14854037 T PT 14854037T PT 14854037 T PT14854037 T PT 14854037T PT 3057965 T PT3057965 T PT 3057965T
Authority
PT
Portugal
Prior art keywords
plk
inhibitor
salt
crystal forms
crystal
Prior art date
Application number
PT14854037T
Other languages
English (en)
Portuguese (pt)
Inventor
Brent Sampson Peter
Feher Miklos
W Pauls Heinz
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of PT3057965T publication Critical patent/PT3057965T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT14854037T 2013-10-18 2014-10-17 Formas de sal e cristal de inibidor de plk-4 PT3057965T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18

Publications (1)

Publication Number Publication Date
PT3057965T true PT3057965T (pt) 2019-04-23

Family

ID=52827507

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14854037T PT3057965T (pt) 2013-10-18 2014-10-17 Formas de sal e cristal de inibidor de plk-4

Country Status (27)

Country Link
US (5) US9884855B2 (enExample)
EP (1) EP3057965B1 (enExample)
JP (1) JP6492072B2 (enExample)
KR (3) KR20160070106A (enExample)
CN (2) CN113248486A (enExample)
AU (1) AU2014336929B9 (enExample)
CA (1) CA2926845C (enExample)
CY (1) CY1121484T1 (enExample)
DK (1) DK3057965T3 (enExample)
EA (1) EA031569B1 (enExample)
ES (1) ES2718603T3 (enExample)
HR (1) HRP20190564T1 (enExample)
HU (1) HUE043194T2 (enExample)
IL (1) IL245038B (enExample)
LT (1) LT3057965T (enExample)
ME (1) ME03377B (enExample)
MX (1) MX359069B (enExample)
NZ (1) NZ718744A (enExample)
PL (1) PL3057965T3 (enExample)
PT (1) PT3057965T (enExample)
RS (1) RS58413B1 (enExample)
SG (1) SG11201602783SA (enExample)
SI (1) SI3057965T1 (enExample)
SM (1) SMT201900124T1 (enExample)
TR (1) TR201902875T4 (enExample)
TW (1) TWI659952B (enExample)
WO (1) WO2015054793A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
PT3057965T (pt) 2013-10-18 2019-04-23 Univ Health Network Formas de sal e cristal de inibidor de plk-4
TWI845482B (zh) 2017-09-08 2024-06-21 加拿大健康網路大學 用於抑制類polo激酶4之組合療法
BR112021021106A2 (pt) * 2019-04-24 2021-12-14 Univ Health Network Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
CN115397429A (zh) * 2019-12-06 2022-11-25 大学健康网络 急性髓性白血病或骨髓增生异常综合征治疗
IL308346A (en) 2021-05-11 2024-01-01 Oric Pharmaceuticals Inc Polo like kinase 4 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8227640B2 (en) * 2007-03-23 2012-07-24 Institute Of Bioengineering And Nanotechnology Palladium catalysts
NZ584760A (en) * 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
JP2011506494A (ja) * 2007-12-21 2011-03-03 ユニバーシティ・ヘルス・ネットワーク 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
CN102428086B (zh) * 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2012121764A1 (en) * 2010-11-25 2012-09-13 Ratiopharm Gmbh Novel salts and polymorphic forms of afatinib
CA2850394C (en) * 2011-10-12 2019-05-21 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
JP6525983B2 (ja) 2013-10-18 2019-06-05 ユニバーシティー ヘルス ネットワーク 膵癌の治療法
PT3057965T (pt) 2013-10-18 2019-04-23 Univ Health Network Formas de sal e cristal de inibidor de plk-4

Also Published As

Publication number Publication date
MX2016004963A (es) 2016-06-28
EA201690755A1 (ru) 2016-09-30
US20160264559A1 (en) 2016-09-15
IL245038B (en) 2019-11-28
SI3057965T1 (sl) 2019-04-30
TR201902875T4 (tr) 2019-03-21
TW201609717A (zh) 2016-03-16
US20190248775A1 (en) 2019-08-15
SMT201900124T1 (it) 2019-05-10
RS58413B1 (sr) 2019-04-30
HRP20190564T1 (hr) 2019-05-17
ME03377B (me) 2020-01-20
MX359069B (es) 2018-09-12
ES2718603T3 (es) 2019-07-03
TWI659952B (zh) 2019-05-21
US10472353B2 (en) 2019-11-12
JP2016537326A (ja) 2016-12-01
US9884855B2 (en) 2018-02-06
WO2015054793A1 (en) 2015-04-23
US20210269428A1 (en) 2021-09-02
SG11201602783SA (en) 2016-05-30
KR20210137251A (ko) 2021-11-17
CA2926845A1 (en) 2015-04-23
KR20220063299A (ko) 2022-05-17
CN105764899A (zh) 2016-07-13
DK3057965T3 (en) 2019-04-01
EP3057965A4 (en) 2017-05-24
EA031569B1 (ru) 2019-01-31
AU2014336929B9 (en) 2019-03-21
CN113248486A (zh) 2021-08-13
US20200140428A1 (en) 2020-05-07
US20180155335A1 (en) 2018-06-07
KR20160070106A (ko) 2016-06-17
EP3057965A1 (en) 2016-08-24
NZ718744A (en) 2021-07-30
KR102395737B1 (ko) 2022-05-10
LT3057965T (lt) 2019-03-12
EP3057965B1 (en) 2019-01-02
JP6492072B2 (ja) 2019-03-27
CA2926845C (en) 2023-06-13
US11667627B2 (en) 2023-06-06
AU2014336929B2 (en) 2018-11-22
US10919886B2 (en) 2021-02-16
HUE043194T2 (hu) 2019-08-28
IL245038A0 (en) 2016-05-31
US10392374B2 (en) 2019-08-27
PL3057965T3 (pl) 2019-08-30
CN105764899B (zh) 2021-06-01
CY1121484T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
ZA201507110B (en) Crystal modifications of elobixibat
EP2975938A4 (en) Inhibitors of prmt5 and methods of their use
EP2968340A4 (en) COMBINING KINASE INHIBITORS AND USES THEREOF
PL3008039T3 (pl) Krystaliczna postać inhibitora mdm2
IL250391A0 (en) Crystalline forms of glutaminase inhibitors
SG11201507897SA (en) Salt of pyrazoloquinoline derivative, and crystal thereof
PT3293176T (pt) Forma cristalina de um inibidor de pde4
IL243728A0 (en) Rorc2 inhibitory trobicycloaryls and methods of using them
IL244268A0 (en) Heterocyclic compounds and methods of use
IL245038A0 (en) Salt and crystal forms of plk–4 inhibitor
PL3019477T3 (pl) Związki heterocykliczne i sposoby ich stosowania
IL240695A0 (en) nme inhibitors and methods of using nme inhibitors
EP2994124A4 (en) INHIBITORS OF METALLO-ß-LACTAMASE-ENZYMES
IL240763B (en) The halopyrazoles as thrombin inhibitors
IL241937B (en) Metastasis inhibitors
GB201312311D0 (en) Uses of enzyme inhibitors
ZA201901155B (en) Salt and crystal of diaza-benzofluorane compound
TH1401007310A (th) เอไมด์ของสารประกอบ 2-อะมิโน-4-เอริลไธอะโซลและเกลือของสารประกอบดังกล่าว